Phase 2 Ovarian Cancer Trial, Recruiting NCT05551208 Sponsor: Chongqing University Cancer Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT05551208
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have ovarian cancer with a specific type (low or high grade serous carcinoma, or endometrioid carcinoma), and you have already had 1 to 3 rounds of platinum-based chemotherapy after your initial surgery.
  • You have at least one tumor that can be measured on a scan.
  • It has been more than 6 months since your last chemotherapy cycle before your cancer came back or got worse.
  • You are between 18 and 75 years old and are generally active and able to carry out daily activities (confirm with trial site).
  • If you are of childbearing age, you have had a negative pregnancy test within 7 days before joining, and you agree to use contraception throughout the trial.
  • Your blood counts are within acceptable levels — including healthy red blood cells, white blood cells, and platelets (confirm with trial site for exact values).
  • Your liver and kidney function test results are within acceptable ranges (confirm with trial site for exact values).

Who may not be able to join:

  • You have used the drug bevacizumab within the last 6 months.
  • You have been diagnosed with another cancer within the last 5 years, or you have cancer that has spread to the brain that has not been treated.
  • You have had a bowel blockage or a hole in your gut in the last 3 months, uncontrolled high blood pressure even with medication, a significant stroke or blood clot in the legs or lungs within the last 6 months, or you have a blood clotting disorder.
  • You have had a heart attack, a serious irregular heartbeat, or moderate to severe heart failure.
  • You currently have a serious infection that is active or cannot be controlled.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Chongqing University Cancer Hospital
Registry
ClinicalTrials.gov
Start date
15 August 2022
Est. completion
30 August 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov